The mRNA era is here. MPM believes the future belongs to oRNA — and Big Pharma wants a seat at the table
If the ultra-fast clinical development of Covid-19 vaccines opened the world’s eyes to the promises of messenger RNA, the subsequent delays in supply offered a crash course on the ultra-complex process of producing them. Even before the formulation and fill-finish steps, mRNA is the precious end product from an arduous journey involving enzyme-aided transcription, modification and purification.
For Bristol Myers Squibb, Novartis Institutes for Biomedical Research, Gilead’s Kite and Astellas, it’s time to rethink the way therapeutic RNA is engineered.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 107,500+ biopharma pros reading Endpoints daily — and it's free.